 |
ImQuest Life Sciences's will maintain a strong and diverse pipeline of compounds for development in the areas of infectious disease and cancer. Through it's partnership with ImQuest BioSciences (www.imquest.com), a service provider with a continuous source of new experimental drugs with significant therapeutic potential, new products with demonstrated value will be added to the development pipeline on an ongoing basis. ImQuest Life Sciences is currently developing novel new agents for HIV and hepatitis B, evaluating potential new drugs in the areas of hepatitis C and influenza, actively progressing topical microbicides towards the clinic and developing novel anti-cancer agents.
|
|
|
 |
| |
|
|
